Mind Medicine (MindMed) Inc. MNMD fell 0.3% during premarket trading after the psychedelic medicines maker sent a letter to its shareholders asking them to vote in favor of its board at its shareholder meeting on June 15, rather than Jake Freeman’s rival nominees. MindMed’s nominees are said to have “essential pharmaceutical industry, corporate governance and capital allocation experience” during a crucial time for the company. MindMed is expecting to receive data from key Phase 2 clinical trials of MM-120, and begin its first sponsored trial for MM-402. MM-110 is a form of LSD, while MM-120 is a more recent…